Integral Diagnostics Balance Sheet Health
Financial Health criteria checks 2/6
Integral Diagnostics has a total shareholder equity of A$301.7M and total debt of A$219.8M, which brings its debt-to-equity ratio to 72.8%. Its total assets and total liabilities are A$744.3M and A$442.6M respectively. Integral Diagnostics's EBIT is A$42.2M making its interest coverage ratio 2. It has cash and short-term investments of A$42.4M.
Key information
72.8%
Debt to equity ratio
AU$219.76m
Debt
Interest coverage ratio | 2x |
Cash | AU$42.44m |
Equity | AU$301.71m |
Total liabilities | AU$442.57m |
Total assets | AU$744.28m |
Recent financial health updates
These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Dec 14We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt
Apr 16Is Integral Diagnostics (ASX:IDX) A Risky Investment?
Dec 26Recent updates
Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
Feb 21Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Nov 22Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Feb 20These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Dec 14Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
May 26Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Feb 28Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Feb 25Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
Oct 29Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Sep 13An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued
Jun 04Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?
May 14Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?
May 03We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt
Apr 16Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?
Mar 27Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?
Mar 17The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About
Mar 07Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend
Feb 25Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?
Feb 23Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?
Feb 13Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price
Feb 03Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)
Jan 24Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?
Jan 14Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return
Jan 05Is Integral Diagnostics (ASX:IDX) A Risky Investment?
Dec 26At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?
Dec 17What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend
Dec 08Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture
Nov 29Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?
Nov 19Financial Position Analysis
Short Term Liabilities: IDX's short term assets (A$74.8M) do not cover its short term liabilities (A$85.7M).
Long Term Liabilities: IDX's short term assets (A$74.8M) do not cover its long term liabilities (A$356.9M).
Debt to Equity History and Analysis
Debt Level: IDX's net debt to equity ratio (58.8%) is considered high.
Reducing Debt: IDX's debt to equity ratio has reduced from 96.6% to 72.8% over the past 5 years.
Debt Coverage: IDX's debt is well covered by operating cash flow (30.1%).
Interest Coverage: IDX's interest payments on its debt are not well covered by EBIT (2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 18:12 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Integral Diagnostics Limited is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Russell Wright | Barclay Pearce Capital Pty Limited |
Thomas Yeo | Barrenjoey Markets Pty Limited |
Saul Hadassin | Barrenjoey Markets Pty Limited |